Which eye drug works better for Diabetes-Related vision loss?
NCT ID NCT07338097
First seen Jan 17, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study compares two common eye injections, aflibercept and bevacizumab, for treating diabetic macular edema (DME), a condition where fluid builds up in the center of the retina and blurs vision. About 116 adults aged 30 to 60 with diabetes for at least 5 years and reduced vision will receive one of the two drugs monthly for two months. The goal is to see which drug leads to greater improvement in vision and reduction of retinal swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMH Institute of Medical Sciences
Multan, Punjab Province, 66000, Pakistan
Conditions
Explore the condition pages connected to this study.